Friday, 20 November 2015
Global Cervical Cancer Diagnostic Tests Market to reach US$8.9 bn by 2020, Propelled by Increased Cervical Cancer Patients
Cancer Care Manitoba demonstrated cancer testing procedures at Winnipeg’s Health Science Centre (HSC) recently, as part of the cervical cancer awareness week. The main focus of this program was to exhibit liquid-based cytology testing. Liquid-based cytology testing is a process that reduces the need for retesting. Samples of cervical cancer are collected through a process called pap test. This method of collecting samples of cervical cancer allows accurate and quick analysis.
In Manitoba, every year, nearly 45 women are identified with cervical cancer and the number is growing rapidly. 80% of cervical cancer cases can be basically prevented by regular screening. Sharon Blady, the minister of health, was present at the Health Science Centre, where various testing methods for cervical cancer were addressed and demonstrated. According to the CervixCheck program, every sexually active women should receive a pap test once every three years, right from the age of 21.
Pap Smear Test Sector to Expand at 6.0% CAGR till 2020
The global cervical cancer diagnostic tests market was valued at US$5.9 bn in 2013 and is expected to reach US$8.9 bn by 2020. The increasing number of cancer patients is expected to propel the global cervical cancer diagnostic tests market at a 6.10% CAGR during the period from 2013 to 2020.
The global cervical cancer diagnostic tests market is segmented on the basis of the type of tests performed and geography. By the type of test, the global cervical cancer diagnostic tests market is classified into HPV testing, pap smear tests, colposcopy, and endocervical curettage procedure. In 2013, the HPV testing sector dominated the global cervical cancer diagnostic tests market. The increasing incidence of HPV infection and increasing number of people who smoke is expected to drive the HPV testing sector during the forecast period. The pap smear test sector is predicted to expand at a 6.0% CAGR till 2020 due to the possibility of early detection of cell abnormalities through this test. Demand for other types of tests such as LEEP and ECC is also expected to increase steadily.
Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/cervical-cancer-diagnostic-tests-market.htm
North America to Account for Highest Global Market Share
By geography, the global cervical cancer diagnostic tests market is classified into North America, Asia Pacific, Europe, and Rest of the World. In 2013, the global cervical cancer diagnostic tests market was led by the North America regional cervical cancer diagnostic tests market. The Asia Pacific regional segment is predicted to register the highest market share by the end of the forecast period due to factors such as easy market penetration, low labor costs, and tax benefits. Some of the prominent players in the global cervical cancer diagnostic tests market are Becton, Hologic, Inc., Guided Therapeutics, Abbott Laboratories, Dickinson and Company, Guided Therapeutics, OncoHealth Corp., Roche Diagnostics, Zilico Ltd., Quest Diagnostics, Inc., and QIAGEN.